Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

CARgenix Holdings

2015 FOUNDED
M&A STATUS
11-20 EMPLOYEES
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Owner and operator of a pharmaceutical company. The company is engaged in providing services related to discovery, development, and delivery of chimeric antigen receptor (CAR) T-cell immunotherapies.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
TNK Therapeutics
Primary Office
  • 199 Grotto Avenue
  • Providence, RI 02906
  • United States

CARgenix Holdings Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore CARgenix Holdings‘s full profile, request access.

Request full access to PitchBook

CARgenix Holdings Executive Team (1)

Name Title Board
Seat
Contact
Info
Jaymin Patel Manager